CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It

Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.